Has the U.S. Healthcare Services Industry valuation changed over the past few years?

Investors are optimistic on the American Healthcare industry, and appear confident in long term growth rates. The industry is trading at a PE ratio of 32.6x which is higher than its 3-year average PE of 24.1x. The industry is trading close to its 3-year average PS ratio of 0.54x.

Which industries have driven the changes within the U.S. Healthcare industry?

Investors are most optimistic about the Managed Healthcare industry which is trading above its 3-year average PE ratio of 23.1x. Analysts are expecting annual earnings growth of 19.4%, which is higher than its past year's earnings decline of 11.4% per year. Investors are most pessimistic about the Healthcare Facilities industry, which is trading close to its 3-year average of 19.6x.

U.S. Healthcare Services Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Mon, 01 Jun 2026	US$975.8b	US$2.2t	US$30.0b	23.2x	32.6x	0.4x
Wed, 29 Apr 2026	US$914.8b	US$2.2t	US$27.6b	24.3x	33.2x	0.4x
Fri, 27 Mar 2026	US$798.0b	US$2.2t	US$27.9b	21.2x	28.6x	0.4x
Sun, 22 Feb 2026	US$861.7b	US$2.2t	US$29.1b	23.9x	29.6x	0.4x
Tue, 20 Jan 2026	US$913.9b	US$2.1t	US$34.8b	23.5x	26.2x	0.4x
Thu, 18 Dec 2025	US$902.8b	US$2.1t	US$34.8b	23.6x	25.9x	0.4x
Sat, 15 Nov 2025	US$891.3b	US$2.1t	US$34.7b	21.6x	25.7x	0.4x
Mon, 13 Oct 2025	US$919.5b	US$2.1t	US$49.3b	21.4x	18.6x	0.4x
Wed, 10 Sep 2025	US$894.9b	US$2.1t	US$49.3b	21x	18.2x	0.4x
Fri, 08 Aug 2025	US$747.6b	US$2.1t	US$49.2b	19.6x	15.2x	0.4x
Sun, 06 Jul 2025	US$859.9b	US$2.1t	US$52.7b	22.2x	16.3x	0.4x
Tue, 03 Jun 2025	US$870.5b	US$2.1t	US$52.5b	21x	16.6x	0.4x
Thu, 01 May 2025	US$917.8b	US$1.7t	US$47.9b	23.9x	19.2x	0.5x
Sat, 29 Mar 2025	US$1.0t	US$1.7t	US$41.5b	24.2x	24.8x	0.6x
Mon, 24 Feb 2025	US$970.5b	US$1.7t	US$40.9b	24.3x	23.8x	0.6x
Wed, 22 Jan 2025	US$1.0t	US$2.0t	US$42.3b	22.9x	24.6x	0.5x
Fri, 20 Dec 2024	US$999.0b	US$2.0t	US$41.4b	21.1x	24.1x	0.5x
Sun, 17 Nov 2024	US$1.1t	US$2.0t	US$41.3b	25.1x	27.5x	0.6x
Tue, 15 Oct 2024	US$1.2t	US$1.9t	US$43.4b	24.7x	27.8x	0.6x
Thu, 12 Sep 2024	US$1.2t	US$1.9t	US$43.3b	27x	27.9x	0.6x
Sat, 10 Aug 2024	US$1.2t	US$1.9t	US$43.3b	28.7x	27.1x	0.6x
Mon, 08 Jul 2024	US$1.1t	US$1.9t	US$43.4b	24.1x	24.7x	0.6x
Wed, 05 Jun 2024	US$1.1t	US$1.9t	US$43.4b	26.5x	25.4x	0.6x
Fri, 03 May 2024	US$1.1t	US$1.9t	US$42.1b	27x	25.6x	0.6x
Sun, 31 Mar 2024	US$1.1t	US$1.8t	US$49.6b	25.9x	23x	0.6x
Tue, 27 Feb 2024	US$1.2t	US$1.8t	US$50.1b	23.9x	23x	0.6x
Thu, 25 Jan 2024	US$1.1t	US$1.8t	US$50.7b	23.9x	22.4x	0.6x
Sat, 23 Dec 2023	US$1.1t	US$1.8t	US$51.2b	22.8x	22.4x	0.6x
Mon, 20 Nov 2023	US$1.1t	US$1.8t	US$51.1b	22.1x	22.2x	0.6x
Wed, 18 Oct 2023	US$1.2t	US$1.8t	US$47.4b	22.9x	24.4x	0.7x
Fri, 15 Sep 2023	US$1.1t	US$1.8t	US$46.8b	21.6x	23.2x	0.6x
Sun, 13 Aug 2023	US$1.1t	US$1.8t	US$46.7b	22.4x	24.4x	0.6x
Tue, 11 Jul 2023	US$1.1t	US$1.7t	US$46.1b	23.3x	23.4x	0.6x
Thu, 08 Jun 2023	US$1.1t	US$1.7t	US$45.8b	22.4x	24.2x	0.6x


US Market	1.58%
Healthcare	0.32%
Healthcare Services	-1.32%
Healthcare Services	-0.84%
Healthcare Distributors	-1.33%
Managed Healthcare	-1.57%
Healthcare Facilities	-1.67%

Company	Last Price	7D	1Y	Valuation
GH Guardant Health	US$129.69	9.0% +US$1.4b	219.3%	PS15.9x
BTSG BrightSpring Health Services	US$61.68	5.4% +US$654.0m	159.1%	PE74.2x
BLLN BillionToOne	US$98.99	15.2% +US$601.2m	n/a	PE183x
HIMS Hims & Hers Health	US$26.15	10.1% +US$555.5m	-53.8%	PS2.6x
GMRS GMR Solutions	US$12.50	13.5% +US$332.5m	n/a	PE78x

Announcement • May 31

Hims & Hers Health, Inc. Expands Benefits With Eight New Health And Wellness Partners

Hims & Hers Health, Inc. announced the expansion of Hims & Hers Benefits, adding eight new partners to the Hims & Hers exclusive program. Joining founding partners Prenuvo and Eight Sleep are Natural Cycles, MyFitnessPal, Ladder, PVOLVE Studios, HelloFresh, Factor, Flo Health, Dexcom, and iFIT - a carefully curated lineup spanning nutrition, fitness, women's health, metabolic monitoring, and connected wellness. The program now offers subscribers 10 ways to access the tools and innovations that support whole-body health, all in one place. Hims & Hers Benefits will continue to grow, with plans to add new partners across every dimension of whole-body health. The program now features ten leading brands spanning nutrition, fitness, women's health, metabolic monitoring, and connected wellness. The new Benefits include: AI coaching that maximizes GLP-1 results with iFIT. Exercise is a powerful complement to GLP-1 treatment — and iFIT makes it personal. Its AI-powered coaching adapts to fitness data, building science-backed workouts around specific goals so can see results faster and build habits that last. Subscribers can get their first three months free ($59.97 value). Build real strength with Ladder. Ladder takes the guesswork out of fitness with expert-programmed strength workouts, built-in progress and nutrition tracking, and coaching that evolves as do, all in one app. Subscribers receive the first three months free (an $89.97 value). Track food, exercise, and calories with MyFitnessPal. Understanding what eat is one of the most powerful tools for lasting change. MyFitnessPal makes it effortless with fast logging AI tools, customized meal plans, exercise tracking, and weight all in one place. Hims & Hers subscribers can receive 15% off the annual Premium+ subscription. Eat better, without the effort, with HelloFresh. Healthy eating starts with what's in kitchen. HelloFresh delivers chef-designed recipes and fresh, pre-portioned ingredients straight to door, making it easier to cook well even on busiest nights. Subscribers receive eleven free meals. Nourish body with Factor. When time is tight but nutrition matters, Factor delivers fresh, never frozen meals that are ready to eat in minutes — no prep, no compromise. Built on real, whole ingredients and free of refined sugars, seed oils, and artificial sweeteners, every dietitian-designed Factor meal is as nutritious as it is convenient. Subscribers can receive 50% off their first box plus free breakfast items for a full year. Track periods, ovulation, pregnancy, perimenopause and more with Flo Health. Flo transforms health data into personalized, clinical-grade insights, tracking a woman’s cycle, ovulation, and hormonal patterns through every stage of her life with the kind of nuance that adapts as their body changes. It's the #1 women's health app in the world. Subscribers can receive 40% off their subscription. Take control of reproductive health with Natural Cycles°. The only FDA-cleared women’s health app powerful enough to prevent pregnancy, Natural Cycles uses body temperature data to deliver personalized, clinically validated insights across every phase of a woman’s cycle. Subscribers can receive 28 days of complimentary access to the NC° app, with the flexibility to connect an existing compatible wearable or use the included NC° Band. Move better, for longer, with PVOLVE Studios. Built on a method that uniquely combines the three pillars of longevity training: strength, mobility, and stability. Using patented resistance equipment and functional movement patterns, PVOLVE sculpts and tones the body, while building deeper mind-body awareness helping members move better, longer. Subscribers can receive discounts on in-studio classes. Stelo by Dexcom, is a small, wearable glucose biosensor worn on the back of the upper arm. Designed for adults 18 and older not using insulin, Stelo is the first FDA-cleared glucose biosensor available without a prescription in the U.S. Built on Dexcom’s most accurate glucose sensing technology, Stelo gives real-time insight into how food, movement, stress, and sleep affect glucose, helping make smarter, more informed decisions every day. Stelo is available as part of Hims & Hers Benefits for eligible subscribers. Underpinning the company’s commitment to put its customers first, Hims & Hers does not profit from these benefits. Instead, 100% of the negotiated benefits are passed directly to active subscribers. Active Hims & Hers subscribers can access these benefits immediately.

Announcement • May 29

Guardant Health Shield Blood Test Included in Updated American Cancer Society Colorectal Cancer Screening Guidelines

Guardant Health, Inc. announced that its FDA-approved Shield blood test is now included in updated American Cancer Society Colorectal Cancer Screening Guidelines. The major screening guideline update recommends Shield as a choice for patients who decline or have not completed stool-based or visual examination screening tests. ACS guidelines now recommend Shield blood-based CRC screening as a new option to expand access and screening participation. Shield is the first and only FDA-approved blood test for primary colorectal cancer screening in average-risk adults age 45 and older and can be completed with just a blood draw during a routine doctor’s visit. CRC is the second leading cancer killer in the United States and the number one cancer killer for adults under 50. The inclusion of Shield in the updated guidelines acknowledges a central challenge in colorectal cancer screening: more than 50 million eligible adults remain unscreened despite established methods like colonoscopy or stool-based testing existing for decades. By recognizing the effectiveness of a blood-based option, the updated guidelines add a new opportunity to reach patients who might otherwise go unscreened. With three out of four CRC deaths among those not up to date with screening, the American Cancer Society noted that “offering multiple, recommended screening options supports informed patient choice and may improve participation, because the most effective screening test is the one that the patient completes.” Guardant’s Shield blood test stood out in guideline evidence for having the highest screening adherence rate compared to traditional colonoscopies and stool-based tests. In the real-world experience with approximately 200,000 patients tested, Shield is proven to increase screening rates with over 90% of patients completing the test. In the pivotal ECLIPSE study, Shield showed its high sensitivity in detecting colorectal cancers and demonstrated sensitivity of 100% in detecting stage II and above cancers. Demonstrating strong real-world evidence and clinical performance published in the New England Journal of Medicine, Shield is the only FDA-approved blood test included in both ACS and National Comprehensive Cancer Network guidelines. Shield is a methylation partitioning cell-free DNA (mp-cfDNA) non-invasive, blood-based screening test that detects alterations associated with colorectal cancer in the blood. It is intended as a screening test for individuals at average risk for the disease, age 45 or older, and is not intended for individuals at high risk for colorectal cancer. The Shield test can be considered in a manner similar to guideline-recommended non-invasive CRC screening options and can be completed during any healthcare visit. A positive Shield result raises concern for the presence of colorectal cancer or advanced adenoma and the patient should be referred for colonoscopy evaluation.

U.S. Healthcare Services Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Hims & Hers Health, Inc. Expands Benefits With Eight New Health And Wellness Partners

First quarter dividend of US$0.20 announced

Cencora, Inc. Appoints Eva C. Boratto as Chief Financial Officer, Effective June 29, 2026

Cigna Tops Q1 Forecasts as Leadership and Portfolio Shifts Signal New Growth Path

Cvs Caremark Delivers Affordability and Access to Glp-1 Weight Management Medications with Expanded Coverage Options

Clover Health Wins Court-Ordered Recalculation on Medicare Star Ratings in Key CMS Ruling

Guardant Health Shield Blood Test Included in Updated American Cancer Society Colorectal Cancer Screening Guidelines

UnitedHealth Group’s Stock Gains After Strong Q1 and Analyst Upgrades Despite Berkshire Exit

McKesson Unit InspiroGene Chosen to Launch Optogenetic Gene Therapy in US Market

HCA Healthcare, Inc. (NYSE:HCA) agreed to acquire The College of Health Care Professions.

HSIC: Ongoing Buybacks And Dental Demand Are Expected To Drive Upside

Price target increased by 7.9% to US$59.29

GMR Solutions Inc. to Report Q1, 2026 Results on Jun 02, 2026

BrightSpring Health Services Delivers 420% Return Since Nasdaq Debut With Upgraded 2026 Outlook

Cardinal Health Lifts 2026 Earnings Outlook as Specialty Segments Drive Q3 EPS Beat

BillionToOne - Starting 2026 Strong